Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
Eligible age
18–49 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.
Sponsor: University of Colorado, Denver
You may qualify if…
- ✓ Age 18-49 years
- ✓ 1\) T1D diagnosis defined as positive T1D-associated antibody(ies) or 2) a clinical diagnosis of T1D plus insulin requirement since diagnosis
- ✓ Insulin pump or automated insulin delivery systems
- ✓ Estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73m2
- ✓ Stable doses of drugs altering cardiovascular and renal function (e.g., Angiotensin-Converting Enzyme Inhibitor (ACEi), Angiotensin Receptor Blocker (ARB), statins, diuretics)
- ✓ BMI 20-45 kg/m2
- ✓ Adequate contraceptive method for females
You may not qualify if…
- ✕ HbA1c \>9%, recent diabetic ketoacidosis (DKA) or hospitalization
- ✕ Major congenital heart disease, anemia, severe non-proliferative retinopathy, proliferative retinopathy
- ✕ History/family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN2), pancreatitis
- ✕ Current/planned pregnancy or nursing
- ✕ Uncontrolled thyroid disease or hypertension (HTN) (≥ 160/100 mm Hg despite optimal therapy)
- ✕ Use of other non-insulin diabetes medications, insulin sensitizing medications, or systemic steroids in past 3 months
- ✕ Use of atypical antipsychotics
- ✕ Significant systemic illness such as cancer
Where it's recruiting
Aurora
Seattle
Source: ClinicalTrials.gov · NCT05819138 · last updated 2026-03-04